Introduction:
Essential Pharma has acquired Renaissance Pharma Ltd with the aim to commercialize the company’s Phase II program Hu14.18K322A in pediatric high-risk neuroblastoma. Neuroblastoma is a rare cancer that affects 800 babies and young children in Europe and the USA every year, with a five-year survival rate of about 50%. The Phase II study of Hu14.18 antibody showed promising results, with a 73.7% event-free 3-year survival rate and an 86% overall survival rate in previously untreated children with high-risk neuroblastoma.
The acquisition adds a second product candidate to Essential Pharma’s rare disease portfolio and underlines the company’s strategy of seeking out clinically differentiated medicines in small patient populations. The acquisition will focus on advancing and obtaining market approval for Hu14.18 in the EU and US markets.
- Essential Pharma has acquired Renaissance Pharma Ltd to commercialize the company’s Phase II program Hu14.18K322A in pediatric high-risk neuroblastoma.
- Neuroblastoma is a rare cancer that affects 800 babies and young children in Europe and the USA every year, with a five-year survival rate of about 50%.
- In the Phase II study, the Hu14.18 antibody achieved a 73.7% event-free 3-year survival rate and an 86% overall survival rate in previously untreated children with high-risk neuroblastoma.
- The acquisition adds a second product candidate to Essential Pharma’s rare disease portfolio and emphasizes the company’s focus on clinically differentiated medicines in small patient populations.
- The acquisition will focus on advancing and obtaining market approval for Hu14.18 in the EU and US markets.
Conclusion:
The acquisition of Renaissance Pharma Ltd by Essential Pharma will facilitate the commercialization of the Phase II program Hu14.18K322A for the treatment of pediatric high-risk neuroblastoma. This acquisition aligns with Essential Pharma’s strategy of developing innovative treatments for rare diseases. The positive results of the Phase II study of the Hu14.18 antibody suggest a potential breakthrough in the treatment of neuroblastoma, with significantly improved survival rates for children with high-risk neuroblastoma. This acquisition represents a significant step forward in the development of targeted therapies for rare diseases.
